DNA

NYSE Ginkgo Bioworks Holdings, Inc. Class A
Oct 16, 2026 · 5:07 PM ET LAST TRADE Market Closed

$10.32 ↑ +0.05 (+0.49%) Trading Up from the previous close of $10.27, $1.48 below the day’s high of $11.80

YTD change
+24.19%
vs 20-day SMA
-8.21%
vs 200-day SMA
+21.50%

Price ranges

Previous day
$10.40 $11.80
open $11.07 close $11.76
+$0.69 (+6.23%)
Today
$10.13 $11.80
open $11.62 now $10.32
-$1.30 (-11.19%)
Past week
$10.40 $13.56
from $11.34 now $10.32
-$1.02 (-8.99%)
Past month
$7.50 $18.22
from $7.84 now $10.32
+$2.48 (+31.63%)
This year
$5.37 $18.22
from $8.31 now $10.32
+$2.01 (+24.19%)

Price & Performance

+3.81 (+47.92%) / 6M

$5.85$9.12$12.39$15.66Apr 16Jul 17Oct 15

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 98.4% away from all-time highs of $634.56
  • DNA is up 24% since the beginning of the year
  • DNA is down 32% over the past 12 months
  • DNA is up 32% over the past 1 month
  • 15% of all DNA investors are betting against DNA
  • Number of investors short DNA has gone up 7% versus last month

DNA reads not so good: price sits above one of the two key moving averages, short interest is rising month over month, the 12-month move is -22.2%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.75
Earnings momentum -10.6% Quarterly EPS growth
Quarterly change -10.6%

Valuation

P/E ratio N/A
Enterprise value $829.3M
Beta 2.27

Balance sheet & scale

IncomeN/A
Revenue$111.9M
Cash$305.1M
Debt$404.1K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNYSE
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $694.9M

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $434.03 +1.86%
MRNA Moderna, Inc. $236.50 +4.51%
RVMD Revolution Medicines, Inc. $189.26 -2.20%
ROIV Roivant Sciences Ltd. $34.04 +1.25%
BNTX BioNTech SE Sponsored ADR $90.20 +1.74%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.